CAR-TCR: Cell Therapy Summit Asia on November 13-14, 2024 in Singapore, Singapore

In the dynamic landscape of cell therapy development, Asia is emerging as a powerhouse, witnessing a remarkable surge in investment and receiving strong regulatory support as companies rapidly progress in clinical and commercial development. Against this backdrop of rapid progress, the 3rd CAR-TCR: Cell Therapy Summit Asia stands as the pivotal gathering for industry players across the APAC region looking to capitalize on Asia's cell therapy boom.

URLs:

Tickets: https://go.evvnt.com/2612151-2?pid=10008

Brochure: https://go.evvnt.com/2612151-3?pid=10008

Time: 9:00 AM - 6:00 PM

Prices:

Academic Pricing - Conference Only: USD 0.50,

Industry Pricing - Conference Only: USD 0.50,

Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Alan Fu, Chief Financial Officer, Nanjing Iaso Biotherapeutic, Cecilia Zhang, Chief Scientific Officer, Biosyngen, Chien-Tsun Kuan, President, Chief Executive Officer and Co-Founder, ARCE Therapeutics, Christy Ma, Chief Executive Officer, SCG Cell Therapy, Danny Soon, Chief Executive Officer, Consortium for Clinical Research and Innovation, Francesca Lim, Chief Medical Officer, Senior Consultant, Deputy Head and Assistant Medical Director, Singapore General Hospital, Singhealth, HSA and ACTRIS, Hao Shen, Chief Scientific Officer, Fosun Kite Biotech, James Li, Co-Founder and Chief Executive Officer, JW Therapeutics, Joe Yeong, Group Leader, A*STAR - Agency for Science Technology and Research, Kok Fei Chan, Research Fellow, Olivia Newton-John Cancer Research Institute, Lim An Eng, Scientist, Bioprocessing Technology Institute (BTI), A*STAR, Lynn Huang, Sr. Manager, PharmaEssentia, Maxwell Wang, Founder and Chief Executive Officer, Skye Med, Rebu Ninan, Head of Commercial and Market Access, Immuneel Therapeutics, Sawyer Xie, Chief Executive Officer, DaRen Biotech, Sudipto Bari, Assistant Director and Head of Translational Services and Regulatory Management, ACTRIS, Ting-Wan Lin, BD/PM Director, GenomeFrontier, Wee Kiat Tan, Co-CEO and COO, CytoMed Therapeutics, Wendell Yang, President and Chief Executive Officer, Imgen BioSciences, Xuan-Hung Nguyen, Chief Scientific Officer, VINMEC Hi Tech Center, Yang Liu, Vice President and Venture Partner, China Credit Enhancement Corporation